WHO ICTRP trial
Biomodulin T-IM-oncological adults post chemotherapy-prevention COVID-19…
RPCEC00000348 · Registro Público Cubano de Ensayos Clínicos (RPCEC) · Recruiting
Key facts
| Trial ID | RPCEC00000348 |
|---|---|
| Public title | Biomodulin T-IM-oncological adults post chemotherapy-prevention COVID-19. Exploratory study |
| Scientific title | Evaluation of the effect and safety of Biomodulin® T on the immune response in post-chemotherapy cancer patients, from a preventive scenario against the COVID-19 viral disease. Exploratory study (COVID-19) - ONCOBIO-T |
| Primary sponsor | National Center for Bioproducts (BioCen). |
| Secondary sponsors | Not applicable |
| Registry | Registro Público Cubano de Ensayos Clínicos (RPCEC) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Countries | Cuba |
| Conditions | COVID-19 COVID-19 SARS-CoV2;Coronavirus Infections;SARS Virus; Coronaviridae Infections;Betacoronavirus;Disease Prevention;Aging ;COVID-19 ;SARS-CoV2 |
| Interventions | Biomodulin T, 1 bulb (3mg / 3mL), 2 times a week, intramuscularly (IM) for 8 weeks.;Immunologic Factors;Injections Intramuscular;Biomodulin T |
| Registration date | Dec 21, 2020 |
| Target size | 60 |
| Secondary IDs | GEC2020BMT030 |
| Registry page | rpcec.sld.cu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: